Новые возможности терапии диссеминированного колоректального рака

Efficacy of three chemotherapy regimens was studied in 99 patients with metastatic colorectal cancer. Patients receiving oxaliplatin plus capecitabine combination demonstrated better immediate and follow-up results than those receiving oxaliplatin + fluorouracil + folinic acid or fluorouracil + folinic acid regimens. Overall response and 2-year survival rates were 45.5±8.6%and19.1%respectivelyinoxaliplatinpluscapecit-8.6% and 19.1% respectively in oxaliplatin plus capecitabine group versus 40.6±8.7and16.3%respectivelyinthefluorouracil+folinicacidgroup.Differencesin.7 and 16.3% respectively in the fluorouracil + folinic acid group. Differences in survival rates between groups with vs without oxaliplatin were statistically significant (p